title: Induction of CYP1A2 by heavy coffee consumption is associated with the CYP1A2 -163C>A polymorphism.
abstract: OBJECTIVE
  To investigate the association of CYP1A2 genetic polymorphisms with the inducing effect of heavy coffee consumption on CYP1A2 activity in Serbian and Swedish populations, and to determine the frequency of the CYP1A2 genetic polymorphisms in Serbs.
  
  
  METHODS
  Using PCR-RFLP and the tag-array minisequencing method, 126 Serbian healthy volunteers were genotyped for -3860G>A, -2467delT, -739T>G, -729C>T, -163C>A, 2159G>A, and 4795G>A. For 64 nonsmoking participants, the data on CYP1A2 activity (plasma paraxanthine/caffeine ratio) and coffee consumption habit were available from our previous study. The data on CYP1A2 genotype, enzyme activity, and coffee consumption from 114 Swedish healthy nonsmoking subjects were included in the analyses.
  
  
  RESULTS
  In Serbs, CYP1A2 polymorphisms -3860G>A, -2467delT, -739T>G, -729C>T, -163C>A, and 2159G>A were found at the frequencies of 0.4, 5.0, 3.4, 0.7, 61.1, and 56.0%, respectively, while 4795G>A was not detected. Significant association of heavy coffee consumption with high CYP1A2 enzyme activity was observed only in carriers of -163 A/A. Increasing effect of -163C>A on CYP1A2 inducibility was found in both Serbian (P=0.022) and Swedish (P=0.016) nonsmoking heavy coffee consumers. There was no significant difference in CYP1A2 enzyme activity among genotypes in non-heavy coffee consumers. The results indicate that 22 and 14% of the phenotypic variability among Serbian and Swedish heavy coffee consumers, respectively, might be explained by -163C>A polymorphism.
  
  
  CONCLUSIONS
  CYP1A2 polymorphism -163C>A has an important increasing effect on CYP1A2 inducibility by heavy coffee consumption and may possibly be a contributing factor for interindividual variations in CYP1A2 enzyme activity.
authors.affiliation: Division of Clinical Pharmacology, Department of Laboratory Medicine, Karolinska Institutet, Karolinska University Hospital, Huddinge, C1: 68 SE-141 86 Stockholm, Sweden.
authors.forename: Natasa
authors.initials: N
authors.lastname: Djordjevic
authors.forename: Roza
authors.initials: R
authors.lastname: Ghotbi
authors.forename: Slobodan
authors.initials: S
authors.lastname: Jankovic
authors.forename: Eleni
authors.initials: E
authors.lastname: Aklillu
mesh_terms: D003069:Coffee / Q000009:adverse effects*; D019388:Cytochrome P-450 CYP1A2 / Q000096:biosynthesis* / Q000235:genetics*; D004790:Enzyme Induction / Q000187:drug effects*; D005260:Female; D005838:Genotype; D006801:Humans; D008297:Male; D011110:Polymorphism, Genetic; D055771:Serbia; D013548:Sweden; D044465:White People / Q000235:genetics
chemical_list: D003069:Coffee; C504573:CYP1A2 protein, human; D019388:Cytochrome P-450 CYP1A2
references.citation: Pharmacogenetics. 1994 Jun;4(3):109-16
references.pmid: 7920690
references.citation: Br J Clin Pharmacol. 2002 Nov;54(5):540-3
references.pmid: 12445035
references.citation: J Biochem. 1999 Apr;125(4):803-8
references.pmid: 10101295
references.citation: Clin Pharmacol Ther. 1998 May;63(5):540-51
references.pmid: 9630827
references.citation: Br J Clin Pharmacol. 1999 Apr;47(4):445-9
references.pmid: 10233211
references.citation: Nucleic Acids Res. 2002 Jul 15;30(14):e70
references.pmid: 12136118
references.citation: Prog Neuropsychopharmacol Biol Psychiatry. 2002 Feb;26(2):261-5
references.pmid: 11817502
references.citation: Mol Pharmacol. 2003 Sep;64(3):659-69
references.pmid: 12920202
references.citation: Br J Clin Pharmacol. 2002 Nov;54(5):504-10
references.pmid: 12445029
references.citation: Ann Clin Biochem. 2005 May;42(Pt 3):216-9
references.pmid: 15949157
references.citation: Eur J Clin Pharmacol. 2010 Jun;66(6):571-8
references.pmid: 20155256
references.citation: Eur J Clin Pharmacol. 1985;28(4):425-8
references.pmid: 4029248
references.citation: Hum Mutat. 2001 Apr;17(4):355-6
references.pmid: 11295848
references.citation: J Hypertens. 2009 Aug;27(8):1594-601
references.pmid: 19451835
references.citation: Pharmacogenomics. 2009 May;10(5):769-78
references.pmid: 19450128
references.citation: Eur J Clin Pharmacol. 2007 Jun;63(6):537-46
references.pmid: 17370067
references.citation: Jpn J Cancer Res. 1999 Sep;90(9):899-902
references.pmid: 10551315
references.citation: Eur J Clin Pharmacol. 2006 Jan;62(1):23-8
references.pmid: 16385402
references.citation: Clin Pharmacol Ther. 1991 Jan;49(1):44-8
references.pmid: 1988240
references.citation: Drug Metab Rev. 2010 May;42(2):268-354
references.pmid: 19961320
references.citation: Antimicrob Agents Chemother. 1992 May;36(5):942-8
references.pmid: 1510417
references.citation: Cancer Epidemiol Biomarkers Prev. 1994 Jul-Aug;3(5):413-21
references.pmid: 7920209
references.citation: J Chromatogr B Biomed Sci Appl. 1998 May 8;709(1):27-34
references.pmid: 9653923
references.citation: Mutat Res. 2005 Nov 10;587(1-2):59-66
references.pmid: 16188490
references.citation: Cancer Epidemiol Biomarkers Prev. 2008 Apr;17(4):895-901
references.pmid: 18398030
references.citation: Eur J Clin Pharmacol. 2008 Apr;64(4):381-5
references.pmid: 18157525
references.citation: Clin Pharmacol Ther. 2007 Feb;81(2):270-83
references.pmid: 17259951
references.citation: Br J Clin Pharmacol. 1998 Feb;45(2):176-8
references.pmid: 9491835
references.citation: Br J Clin Pharmacol. 2003 Jan;55(1):68-76
references.pmid: 12534642